European Respiratory Society (ERS) International Congress 2021: Focus PF-ILD

Principali contenuti scientifici presentati al Congresso ERS, 5-8 Settembre 2021

Scarica il report sulle ultime novità in ambito PF-ILD:

• Diagnosis, monitoring and treatment recommendations

• Biomarkers

• Clinical trials

• Real-world evidence

Scarica lo slide kit sulle principali evidenze emerse in PF-ILD:

• Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial   
  (Kreuter M et al.)

• Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON   
  (Wuyts WA et al.)

• Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?   
  (Wijsenbeek MS et al.)

• Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases (ILDs): pooled data from four trials (Valenzuela C et al)

• Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data   
  (Maher T et al)